• In May 2026, Halozyme Therapeutics, Inc. reported first-quarter 2026 results showing revenue of US$376.71 million and net income of US$150.05 million, reaffirmed its 2026 revenue guidance of US$1.71 billion to US$1.81 billion, announced a new share repurchase authorization of up to US$1.00 billion through 2028, and confirmed completion of a prior buyback program.
• Earlier that month, GSK announced a global collaboration and license agreement to use Halozyme’s ENHANZE technology across multiple oncology targets, adding a new potential royalty and milestone stream that could broaden Halozyme’s partner base and reinforce the role of subcutaneous drug delivery in cancer care.
• Next, we’ll examine how the new GSK ENHANZE collaboration may reshape Halozyme’s investment narrative and future royalty mix.

Capitalize on the AI infrastructure supercycle with our selection of the 43 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme, you need to believe ENHANZE can remain a preferred way to convert or launch biologics as subcutaneous therapies, supporting recurring royalties from a concentrated partner base. Right now, the key near term catalyst is how fast new ENHANZE programs translate into commercial royalties, while the biggest risk remains dependence on a handful of blockbuster partners. The GSK deal and solid Q1 results support that core story, but do not remove partner concentration or patent risks.

Among the recent announcements, the new global GSK license for ENHANZE looks most relevant. It adds another large pharma partner in oncology and creates a fresh stream of potential milestones and royalties, which could, over time, modestly diversify Halozyme’s reliance on J&J, Roche and argenx. That said, the economics and timelines of GSK’s ENHANZE programs are still uncertain, so the headline catalyst does not fully offset the existing concentration and IP risks.

Yet despite the strong GSK tie up, investors should be aware that concentrated royalty exposure still leaves Halozyme vulnerable if...

Halozyme Therapeutics' narrative projects $2.2 billion revenue and $1.1 billion earnings by 2029.

Uncover how Halozyme Therapeutics' forecasts yield a $85.78 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Some bullish analysts already expected Halozyme to reach about US$2.2 billion in revenue and US$1.1 billion in earnings, and they see IP litigation outcomes as a swing factor, so compared with the baseline focus on partner and pricing risk, this more optimistic view highlights how far opinions can differ and invites you to weigh how Q1 and the new GSK deal might shift those expectations.

Explore 5 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.